|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
SG11201400513PA
(en)
|
2011-09-08 |
2014-06-27 |
Yeda Res & Dev |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US20150166984A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting alpha-antitrypsin point mutations
|
|
EP3613854A1
(en)
|
2014-03-05 |
2020-02-26 |
National University Corporation Kobe University |
Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
|
|
US11390921B2
(en)
|
2014-04-01 |
2022-07-19 |
Adaptive Biotechnologies Corporation |
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
|
|
IL292038B2
(en)
|
2014-04-23 |
2024-12-01 |
Juno Therapeutics Inc |
Methods for enriching or producing immune cell populations for adoptive therapy
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
KR102546296B1
(ko)
*
|
2014-10-31 |
2023-06-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
HRP20220890T1
(hr)
|
2015-02-06 |
2022-10-14 |
National University Of Singapore |
Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
|
|
BR112017020750A2
(en)
*
|
2015-03-27 |
2018-06-26 |
President And Fellows Of Harvard College |
modified t-cells and methods of producing and using them
|
|
CN107787367B
(zh)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
AU2016291825B2
(en)
|
2015-07-16 |
2022-08-11 |
Yeda Research And Development Co. Ltd. |
Genetically modified anti-third party central memory T cells and use of same in immunotherapy
|
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
|
ES2768984T3
(es)
|
2015-10-05 |
2020-06-24 |
Prec Biosciences Inc |
Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
|
|
ES2803728T3
(es)
|
2015-10-05 |
2021-01-29 |
Prec Biosciences Inc |
Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
CN108495932B
(zh)
|
2015-11-27 |
2022-08-09 |
国立大学法人神户大学 |
用于特异性转换靶向dna序列的核酸碱基的单子叶植物的基因组序列的转换方法、及其使用的分子复合体
|
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
JP7114477B2
(ja)
|
2015-12-16 |
2022-08-08 |
グリットストーン バイオ インコーポレイテッド |
新生抗原の特定、製造、および使用
|
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
KR20190039115A
(ko)
*
|
2016-07-05 |
2019-04-10 |
더 존스 홉킨스 유니버시티 |
암을 치료하기 위한 crispr/cas9-기반 조성물 및 방법
|
|
SG11201900038QA
(en)
*
|
2016-07-05 |
2019-02-27 |
Univ Johns Hopkins |
Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
|
|
CN106191062B
(zh)
*
|
2016-07-18 |
2019-06-14 |
广东华南疫苗股份有限公司 |
一种tcr-/pd-1-双阴性t细胞及其构建方法
|
|
US12350349B2
(en)
|
2016-08-03 |
2025-07-08 |
Washington University |
Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
|
US12012598B2
(en)
|
2016-08-12 |
2024-06-18 |
Toolgen Incorporated |
Manipulated immunoregulatory element and immunity altered thereby
|
|
IL264439B2
(en)
*
|
2016-08-17 |
2024-08-01 |
Factor Bioscience Inc |
non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CN106399375A
(zh)
*
|
2016-08-31 |
2017-02-15 |
南京凯地生物科技有限公司 |
利用CRISPR/Cas9敲除人PD‑1基因构建靶向CD19CAR‑T细胞的方法
|
|
CN106480097A
(zh)
*
|
2016-10-13 |
2017-03-08 |
南京凯地生物科技有限公司 |
利用CRISPR/Cas9技术敲除人PD‑1基因构建可靶向MSLN新型CAR‑T细胞的方法及其应用
|
|
KR20190062505A
(ko)
*
|
2016-10-03 |
2019-06-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Hpv-특이적 결합 분자
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
EP3532075A4
(en)
*
|
2016-10-27 |
2020-07-08 |
Intima Bioscience, Inc. |
VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
|
|
US20200095574A1
(en)
*
|
2016-11-07 |
2020-03-26 |
Genovie Ab |
An engineered multi-component system for identification and characterisation of t-cell receptors, t-cell antigens and their functional interaction
|
|
EP3535393B1
(en)
|
2016-11-07 |
2021-09-22 |
Genovie AB |
A two-part device for t-cell receptor synthesis and stable genomic integration to tcr-presenting cells
|
|
EP4332232A3
(en)
|
2016-11-07 |
2024-05-08 |
Genovie AB |
An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens
|
|
GB201622044D0
(en)
*
|
2016-12-22 |
2017-02-08 |
Ucl Business Plc |
T cell-targeted T cells
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
WO2018132508A1
(en)
*
|
2017-01-10 |
2018-07-19 |
The General Hospital Corporation |
Methods and compositions relating to ex vivo culture and modulation of t cells
|
|
AU2018208614A1
(en)
*
|
2017-01-10 |
2019-07-11 |
The General Hospital Corporation |
Modified T cells and methods of their use
|
|
ES3064681T3
(en)
*
|
2017-01-18 |
2026-04-28 |
Yeda Res & Dev |
Genetically modified veto cells and use of same in immunotherapy
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
KR20190123328A
(ko)
|
2017-03-09 |
2019-10-31 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
암 백신
|
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
|
CN110913690A
(zh)
*
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
用于低温储存的方法
|
|
KR20190130608A
(ko)
*
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
IL306092A
(en)
|
2017-03-23 |
2023-11-01 |
Harvard College |
Nucleic base editors that include nucleic acid programmable DNA binding proteins
|
|
US10934336B2
(en)
|
2017-04-13 |
2021-03-02 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
|
|
US12029760B2
(en)
*
|
2017-05-04 |
2024-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for gene editing in T cells using CRISPR/Cpf1
|
|
US12275963B2
(en)
|
2017-05-08 |
2025-04-15 |
Toolgen Incorporated |
Artificially manipulated immune cell
|
|
JP7170666B2
(ja)
*
|
2017-05-08 |
2022-11-14 |
プレシジョン バイオサイエンシズ，インク． |
操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
BR112019023608A2
(pt)
*
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CA3067244A1
(en)
*
|
2017-06-12 |
2018-12-20 |
Children's Healthcare Of Atlanta, Inc. |
T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies
|
|
MY200418A
(en)
|
2017-06-15 |
2023-12-25 |
Univ California |
Targeted non-viral dna insertions
|
|
WO2018236909A1
(en)
*
|
2017-06-20 |
2018-12-27 |
La Jolla Institute For Allergy And Immunology |
T-MODIFIED LYMPHOCYTE RECEPTORS AND METHODS OF USE IN INFLAMMATORY RESPONMS MODULATION AND ATHEROSCLEROSIS TREATMENT
|
|
JP2020528738A
(ja)
*
|
2017-06-20 |
2020-10-01 |
ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． |
ｉｎ ｖｉｔｒｏでＴ細胞中のターゲット遺伝子をノックアウトするための方法及び前記方法で使用されるｃｒＲＮＡ
|
|
EP4775669A2
(en)
|
2017-06-30 |
2026-07-15 |
Precision Biosciences, Inc. |
Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
|
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
CA3071282A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
EP3441461A1
(en)
*
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
CN109456943A
(zh)
*
|
2017-09-06 |
2019-03-12 |
亘喜生物科技（上海）有限公司 |
通用型嵌合抗原受体t细胞制备技术
|
|
WO2019047932A1
(zh)
*
|
2017-09-08 |
2019-03-14 |
科济生物医药（上海）有限公司 |
基因工程化的t细胞及应用
|
|
EP3686275A4
(en)
*
|
2017-09-18 |
2021-09-29 |
Edigene Inc. |
GENE EDITING LYMPHOCYTE T AND RELATED USE
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
CN109517820B
(zh)
*
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
|
CN107630006B
(zh)
*
|
2017-09-30 |
2020-09-11 |
山东兴瑞生物科技有限公司 |
一种制备tcr与hla双基因敲除的t细胞的方法
|
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
CN117820491A
(zh)
*
|
2017-10-10 |
2024-04-05 |
国立大学法人广岛大学 |
使用铂talen的t细胞受体的完全取代技术
|
|
TWI814745B
(zh)
|
2017-10-10 |
2023-09-11 |
國立大學法人廣島大學 |
使用效應T細胞(Teff)抗原受體之抗原特異性控制性T細胞(Treg)之製出技術
|
|
CN111465989B
(zh)
|
2017-10-10 |
2024-06-25 |
磨石生物公司 |
使用热点进行的新抗原鉴别
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
CN107759700A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd19抗原的转基因t细胞及其制备方法与应用
|
|
CN107827989A
(zh)
*
|
2017-10-18 |
2018-03-23 |
银丰生物工程集团有限公司 |
靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用
|
|
CN107759699A
(zh)
*
|
2017-10-18 |
2018-03-06 |
银丰生物工程集团有限公司 |
靶向cd30抗原的转基因t细胞及其制备方法与应用
|
|
CN107723275B
(zh)
*
|
2017-10-20 |
2020-09-04 |
重庆精准生物技术有限公司 |
通用型car-t细胞及其制备方法和应用
|
|
SG11202003798TA
(en)
|
2017-10-27 |
2020-05-28 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
|
EP3703712A4
(en)
|
2017-10-30 |
2021-09-22 |
PACT Pharma, Inc. |
EDITING PRIMARY CELL GENES
|
|
CN107916269B
(zh)
*
|
2017-11-17 |
2020-12-11 |
山东兴瑞生物科技有限公司 |
靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用
|
|
AU2018373154B2
(en)
|
2017-11-22 |
2025-08-07 |
Seattle Project Corp. |
Reducing junction epitope presentation for neoantigens
|
|
WO2019106163A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Cellectis |
Reprogramming of genetically engineered primary immune cells
|
|
AU2018383712B2
(en)
*
|
2017-12-11 |
2025-09-04 |
Editas Medicine, Inc. |
Cpf1-related methods and compositions for gene editing
|
|
US11738047B2
(en)
|
2017-12-12 |
2023-08-29 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting NY-ESO-1 and methods of use thereof
|
|
CA3082204A1
(en)
*
|
2017-12-13 |
2019-06-20 |
Janssen Biotech, Inc. |
Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019129851A1
(en)
*
|
2017-12-29 |
2019-07-04 |
Cellectis |
Method for improving production of car t cells
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN108559760A
(zh)
*
|
2018-01-09 |
2018-09-21 |
陕西师范大学 |
基于CRISPR靶向基因组修饰技术建立荧光素酶knock-in细胞系的方法
|
|
KR102327512B1
(ko)
|
2018-01-12 |
2021-11-17 |
주식회사 큐로셀 |
이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
|
|
US12215154B2
(en)
|
2018-01-19 |
2025-02-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting γδ T cells with chimeric antigen receptors
|
|
CN108103027B
(zh)
*
|
2018-02-02 |
2021-12-24 |
中国医学科学院血液病医院（血液学研究所） |
高效率血细胞重编程同时实现基因编辑的方法
|
|
SG11202007622SA
(en)
*
|
2018-02-11 |
2020-09-29 |
Memorial Sloan Kettering Cancer Center |
Non-hla restricted t cell receptors and uses thereof
|
|
IL276839B1
(en)
|
2018-02-27 |
2026-05-01 |
Gritstone Bio Inc |
Neoantigen identification using pan-allelic models
|
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
|
US11447769B2
(en)
|
2018-03-27 |
2022-09-20 |
The Trustees Of The University Of Pennsylvania |
Modified immune cells having enhanced function and methods for screening for same
|
|
US11649455B2
(en)
|
2018-03-30 |
2023-05-16 |
University Of Geneva |
Micro RNA expression constructs and uses thereof
|
|
KR20200138334A
(ko)
|
2018-04-02 |
2020-12-09 |
팩트 파마, 인크. |
펩티드-MHC comPACT
|
|
CN112585276A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
产生表达重组受体的细胞的方法和相关组合物
|
|
CN112566698A
(zh)
*
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T细胞受体和表达该t细胞受体的工程化细胞
|
|
CN112585277A
(zh)
|
2018-04-05 |
2021-03-30 |
朱诺治疗学股份有限公司 |
表达重组受体的t细胞、相关多核苷酸和方法
|
|
KR102617818B1
(ko)
|
2018-04-12 |
2023-12-27 |
프리시젼 바이오사이언시스 인코포레이티드 |
인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
|
|
CN108490174B
(zh)
*
|
2018-04-18 |
2022-06-24 |
上海尚珞生物医药科技有限公司 |
检测car-t细胞的方法及其应用
|
|
JP7584127B2
(ja)
*
|
2018-04-26 |
2024-11-15 |
ベイラー カレッジ オブ メディスン |
活性化された病原性ｔ細胞およびｎｋ細胞の選択的標的化のための自己／同種免疫防御受容体
|
|
US20200063100A1
(en)
|
2018-05-11 |
2020-02-27 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
CN112654710A
(zh)
|
2018-05-16 |
2021-04-13 |
辛瑟高公司 |
用于指导rna设计和使用的方法和系统
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
IL279063B2
(en)
*
|
2018-05-31 |
2026-05-01 |
Washington University St Louis |
Chimeric antigen receptor T cells for cancer treatment
|
|
JP2021525518A
(ja)
*
|
2018-05-31 |
2021-09-27 |
ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ |
細胞をゲノム編集及び活性化するための方法
|
|
CN110616188B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种通用型car-t细胞及其制备方法和应用
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
CN112805369A
(zh)
*
|
2018-08-08 |
2021-05-14 |
南特生物公司 |
重组cd1限制性t细胞及方法
|
|
CN110904045A
(zh)
*
|
2018-09-17 |
2020-03-24 |
中国科学院动物研究所 |
经修饰的t细胞、其制备方法及用途
|
|
AU2019341365A1
(en)
*
|
2018-09-21 |
2021-05-27 |
Crage Medical Co., Limited |
Method for gene editing of cell on the basis of CRISPR/Cas system
|
|
JP7250031B2
(ja)
*
|
2018-09-25 |
2023-03-31 |
公益財団法人微生物化学研究会 |
新規ウイルスベクターおよびその製造方法と使用方法
|
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
CN109295106B
(zh)
*
|
2018-09-30 |
2020-07-24 |
北京鼎成肽源生物技术有限公司 |
一种hafft1细胞
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CA3116132A1
(en)
*
|
2018-10-16 |
2020-04-23 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US12146157B2
(en)
*
|
2018-11-07 |
2024-11-19 |
Crispr Therapeutics Ag |
Anti-PTK7 immune cell cancer therapy
|
|
EA202191257A1
(ru)
|
2018-11-07 |
2021-12-06 |
Криспр Терапьютикс Аг |
Противораковая терапия на основе иммуноцитов, связывающих liv1
|
|
SG11202103832SA
(en)
*
|
2018-11-07 |
2021-05-28 |
Crispr Therapeutics Ag |
Anti-cd33 immune cell cancer therapy
|
|
WO2020103013A1
(en)
*
|
2018-11-21 |
2020-05-28 |
Nanjing Bioheng Biotech Co., Ltd |
Modified t cells and uses thereof
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
CN109722437B
(zh)
*
|
2018-12-29 |
2020-01-07 |
广州百暨基因科技有限公司 |
一种通用型car-t细胞及其制备方法和用途
|
|
CN109652378B
(zh)
*
|
2018-12-29 |
2020-04-24 |
广州百暨基因科技有限公司 |
一种功能增强的通用型car-t细胞及其制备方法和用途
|
|
KR20210116526A
(ko)
*
|
2019-01-16 |
2021-09-27 |
빔 테라퓨틱스, 인크. |
증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
|
|
WO2020150633A1
(en)
|
2019-01-18 |
2020-07-23 |
Orthobio Therapeutics, Inc. |
Gene editing to improve joint function
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
IL316576A
(en)
|
2019-02-12 |
2024-12-01 |
Pact Pharma Inc |
Preparations and methods for identifying antigen-specific T cells
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
AU2020226893B2
(en)
*
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CA3130825A1
(en)
|
2019-02-22 |
2020-08-27 |
Garvan Institute Of Medical Research |
Methods of modulating immune response via snvs of a20 that can "tune" the immune system of a subject
|
|
CN109913501B
(zh)
*
|
2019-03-01 |
2022-08-16 |
华东师范大学 |
一种靶向cd152的复制缺陷性重组慢病毒car-t转基因载体及构建方法
|
|
CN111676195A
(zh)
*
|
2019-03-11 |
2020-09-18 |
北京卡替医疗技术有限公司 |
一种治疗t细胞肿瘤的ucar免疫细胞
|
|
US12473346B2
(en)
|
2019-03-18 |
2025-11-18 |
Ludwig Institute For Cancer Research Ltd |
A2/NY-ESO-1 specific t cell receptors and uses thereof
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
CA3130701A1
(en)
*
|
2019-03-21 |
2020-09-24 |
Yajin Ni |
Methods for enhancing tcr.alpha..beta.+cell depletion efficiency
|
|
EP4332115A3
(en)
|
2019-04-03 |
2024-05-29 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CA3138633A1
(en)
*
|
2019-04-30 |
2020-11-05 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質－金属水酸化物錯体およびその方法
|
|
CN112430575B
(zh)
*
|
2019-08-26 |
2024-01-19 |
深圳市菲鹏生物治疗股份有限公司 |
通用型car-t细胞及其制备方法、应用以及抗肿瘤药物
|
|
PH12022550548A1
(en)
*
|
2019-09-06 |
2023-11-20 |
Crispr Therapeutics Ag |
Genetically engineered t cells having improved persistence in culture
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
AU2020382219A1
(en)
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
WO2021095012A1
(en)
*
|
2019-11-13 |
2021-05-20 |
Crispr Therapeutics Ag |
Methods of manufacturing car-t cells
|
|
EP4061927A4
(en)
*
|
2019-11-20 |
2024-11-13 |
Cartherics Pty. Ltd. |
METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION
|
|
US20210155924A1
(en)
*
|
2019-11-27 |
2021-05-27 |
Stitch Bio, Llc |
Methods and compositions for inducing tumor cell death
|
|
JP7670358B2
(ja)
*
|
2020-01-02 |
2025-04-30 |
寧波茂行生物医薬科技有限公司 |
修飾された免疫エフェクター細胞及びその調製方法
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
WO2021147891A1
(zh)
*
|
2020-01-21 |
2021-07-29 |
苏州克睿基因生物科技有限公司 |
一种经修饰的免疫效应细胞及其用途
|
|
JP2023511965A
(ja)
*
|
2020-01-23 |
2023-03-23 |
カンステム バイオテック カンパニー リミテッド |
Ｏｆｆ－ｔｈｅ－ｓｈｅｌｆ幹細胞および免疫細胞、それを含む薬学的組成物
|
|
JP2023515270A
(ja)
*
|
2020-04-21 |
2023-04-12 |
テンパス・ラボズ・インコーポレイテッド |
Ｔｃｒ／ｂｃｒプロファイリング
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
CN113684258B
(zh)
*
|
2020-05-18 |
2024-08-20 |
上海赛比曼生物科技有限公司 |
用于检测鼠源tcr转基因拷贝数的试剂盒及方法
|
|
AU2021297458B2
(en)
*
|
2020-06-25 |
2026-06-18 |
The Methodist Hospital |
Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
WO2022012531A1
(zh)
*
|
2020-07-14 |
2022-01-20 |
苏州克睿基因生物科技有限公司 |
一种经修饰的免疫细胞的制备方法
|
|
CA3181118A1
(en)
*
|
2020-07-15 |
2022-01-20 |
Yali ZHOU |
Engineered immune cell for allotransplantation
|
|
AU2021308079A1
(en)
*
|
2020-07-16 |
2023-03-02 |
Orthobio Therapeutics, Inc. |
Gene editing to improve joint function
|
|
WO2022040454A1
(en)
*
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
AU2021360477A1
(en)
*
|
2020-10-13 |
2023-06-15 |
The Trustees Of The University Of Pennsylvania |
In vivo targeting of t cells for mrna therapeutics
|
|
WO2022082030A2
(en)
|
2020-10-15 |
2022-04-21 |
Gritstone Bio, Inc. |
Antigen-binding proteins and related methods of use
|
|
CN112266899A
(zh)
*
|
2020-10-26 |
2021-01-26 |
北京卡替医疗技术有限公司 |
修饰的免疫细胞及其用途
|
|
EP4247843A1
(en)
*
|
2020-11-23 |
2023-09-27 |
Ludwig-Maximilians-Universität München |
Cd28-targeting chimeric antigen receptor (car) t cells, methods of generation and uses thereof
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN112899227B
(zh)
*
|
2021-01-14 |
2022-09-13 |
中国科学院微生物研究所 |
一种调控辅助性t细胞功能的方法
|
|
WO2022155503A1
(en)
|
2021-01-14 |
2022-07-21 |
Gritstone Bio, Inc. |
Multi-specific antibodies and methods of use
|
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
|
KR20230151518A
(ko)
*
|
2021-03-04 |
2023-11-01 |
알로젠 테라퓨틱스 인코포레이티드 |
치료 세포를 동종이계 거부반응 및 활성화 유도된 세포 사멸로부터 보호하기 위한 FasL 발현 및 FasR 유전자 녹아웃
|
|
US20240148791A1
(en)
*
|
2021-03-08 |
2024-05-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for assessing and treating t cell dysfunction
|
|
US12617864B2
(en)
|
2021-04-12 |
2026-05-05 |
Medgene Therapeutics, Inc. |
Methods of activating and proliferating exhausted CD8 T cells, CD8 T cells with enhanced activity prepared by the same, and uses thereof
|
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
|
JP2024536839A
(ja)
*
|
2021-09-29 |
2024-10-08 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
非移植ｃｄ８除去同種ドナーリンパ球輸注の有効性を高め、毒性を低減する方法および組成物
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
CN113980907B
(zh)
*
|
2021-12-24 |
2022-03-15 |
山东兴瑞生物科技有限公司 |
一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用
|
|
CN114591963B
(zh)
*
|
2022-05-10 |
2022-07-19 |
上海优替济生生物医药有限公司 |
sgRNA及利用其构建GM-CSF(-)细胞的方法
|
|
KR20250061756A
(ko)
|
2022-09-08 |
2025-05-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
|
|
JP2025531296A
(ja)
*
|
2022-09-19 |
2025-09-19 |
エメンドバイオ・インコーポレイテッド |
Ｐｄｃｄ１の両アレルノックアウト
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024121426A1
(en)
*
|
2022-12-09 |
2024-06-13 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Method for optimizing t cells for immuno-therapy
|
|
EP4630567A2
(en)
*
|
2022-12-09 |
2025-10-15 |
Research Institute at Nationwide Children's Hospital |
Chimeric antigen receptor (car) t cells and uses thereof
|
|
US20260232729A1
(en)
|
2023-02-03 |
2026-08-13 |
C3S2 Gmbh |
Methods for non-viral manufacturing of engineered immune cells
|
|
JP2026505337A
(ja)
*
|
2023-02-10 |
2026-02-13 |
南京北恒生物科技有限公司 |
機能が強化した細胞療法
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|
|
CN122122295A
(zh)
*
|
2023-10-18 |
2026-05-29 |
北京沙砾生物医药股份有限公司 |
一种鉴定靶标的方法及其应用
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|